Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine plus clobetasol versus clobetasol alone for vitiligo
IRCT20221020056251N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of fluoxetine and clobetasol in Vitiligo (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Lesion size. Started Feb 2023; status: completed.
02
Drugs
fluoxetineclobetasol
03
Conditions
Vitiligo
Beyond the preview
Go deeper on IRCT20221020056251N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221020056251N1.